Cardiology

The US FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor, to reduce LDL-C in adults with hypercholesterolemia, including HeFH.

Catch up on the 7 FDA drug approvals most relevant to primary care, including new options for hypertension, weight management, acne, and more.

SLEEP 2026: A sleep expert discusses screening tools, referral pathways, and why sleep disorders matter for cardiometabolic health in primary care.

A deep learning ECG model identified a high-risk group with a 7.0% annual sudden cardiac death rate in a new study.

SLEEP 2026: Virend Somers, MD, PhD, details how busy primary care physicians can address sleep in routine visits.

SLEEP 2026: Virend Somers, MD, of Mayo Clinic, outlines why sleep has been added to the AHA's Life’s Essential 8.

The first guideline for cardiovascular-kidney-metabolic syndrome details staging, screening, risk assessment, and treatment.

Payal Kohli, MD, discusses how baxdrostat may fit into hypertension care, including efficacy, patient selection, and monitoring needs.

Kohli discusses the FDA approval of baxdrostat (Baxfendy), the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.

VERVE-102 reduced PCSK9 and LDL-C after one infusion in early Heart-2 data for patients needing additional lipid lowering.

FDA approved baxdrostat for adults with hypertension not controlled on other agents, adding a new aldosterone-targeting option.

South London data show stroke rates climbing again, hitting Black communities and poorer areas hardest, and exposing gaps in prevention and follow-up.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

The TRIDENT trial shows a once-daily triple BP pill after intracerebral hemorrhage improves control and lowers recurrent stroke and cardiovascular events.

Steven Nissen, MD, discusses new SURPASS-CVOT data showing reduced cardiorenal events and mortality with tirzepatide vs dulaglutide.

A secondary analysis of the FINEARTS-HF trial demonstrated consistent treatment efficacy in patients with and without a history of IHD. Details from study author Jawad Butt, MD, here.

Phase 3 CORALreef AddOn shows oral PCSK9 inhibitor enlicitide cuts LDL 65% on statins, potentially easing primary care lipid control.

New AHA/ASA stroke guidance widens thrombolysis and EVT access, eases imaging, and updates BP/glucose targets—what frontline teams need now.

Phase 3 data show oral PCSK9 inhibitor enlicitide reduced LDL-C by 64.6% at 8 weeks vs oral nonstatins in high-risk patients.

New evidence suggests lowering LDL-C to 44 mg/dL with PCSK9 therapy may better protect high-risk patients with diabetes, aligning primary prevention targets with secondary prevention.

ACC 2026: A new secondary analysis of the VESALIUS-CV study shows evolocumab cuts heart attacks, strokes and deaths in high‑risk patients with type 2 diabetes.

Your daily dose of the clinical news you may have missed.

ACC 2026. Evolocumab reduced first CV events by 31% in high-risk diabetes without ASCVD, supporting earlier LDL-C intensification.

New data to be presented at ACC 2026 shows 6 hours of daily screen time may lead to higher BP, LDL-C, BMI, and nicotine use, independent of exercise.

Dr Bhatt emphasizes that clinical targets for biological variables like blood pressure and LDL-C are crucial for effective patient care.